Neutralization of staphylococcal enterotoxin B by an aptamer antagonist

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2072-2077

  Wang, Kaiyu ^a,b,c   Gan, Longjie ^c   Jiang, Li ^c   Zhang, Xianhui ^c   Yang, Xiangyue ^a,b,c   Chen, Min ^a,b,c   Lan, Xiaopeng ^a,b,c  

^a FUZHOU GENERAL HOSPITAL   (China)

^b XIAMEN UNIVERSITY   (China)

^c FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; FLUORESCEIN ISOTHIOCYANATE; GALACTOSAMINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; STAPHYLOCOCCUS ENTEROTOXIN B; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; ENTEROTOXIN; ENTEROTOXIN B, STAPHYLOCOCCAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISSOCIATION CONSTANT; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SENSITIZATION; SEQUENCE ANALYSIS; TOXIC SHOCK SYNDROME; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOLOGY; BIOSYNTHESIS; COMBINATORIAL CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; MICROBIOLOGY; MOLECULAR CLONING; MONOCYTE; SHOCK, SEPTIC;

ANIMALS; CELL PROLIFERATION; CLONING, MOLECULAR; COMPUTATIONAL BIOLOGY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; ENTEROTOXINS; FEMALE; GALACTOSAMINE; HUMANS; MICE; MICE, INBRED BALB C; MONOCYTES; SELEX APTAMER TECHNIQUE; SHOCK, SEPTIC;

EID: 84928814984     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04414-14     Document Type: Article

References (35)

1. Fraser JD, Proft T. 2008. The bacterial superantigen and superantigen-like proteins. Immunol Rev 225:226-243. http://dx.doi.org/10.1111/j.1600-065X.2008.00681.x.
2. Sundberg EJ, Deng L, Mariuzza RA. 2007. TCR recognition of peptide/MHCclass II complexes and superantigens. Semin Immunol 19:262-271. http://dx.doi.org/10.1016/j.smim.2007.04.006.
3. Libbey JE, Cusick MF, Fujinami RS. 2014. Role of pathogens in multiple sclerosis. Int Rev Immunol 33:266-283. http://dx.doi.org/10.3109/08830185.2013.823422.
4. Lindsay CD, Griffiths GD. 2013. Addressing bioterrorism concerns: options for investigating the mechanism of action of Staphylococcus aureus enterotoxin B Hum Exp Toxicol 32:606-619. http://dx.doi.org/10.1177/0960327112458941.
5. Hudson LC, Seabolt BS, Odle J, Bost KL, Stahl CH, Piller KJ. 2013. Sublethal staphylococcal enterotoxin B challenge model in pigs to evaluate protection following immunization with a soybean-derived vaccine. Clin Vaccine Immunol 20:24-32. http://dx.doi.org/10.1128/CVI.00526-12.
6. Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie JB. 2001. Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun 69:875-884. http://dx.doi.org/10.1128/IAI.69.2.875-884.2001.
7. Varshney AK, Wang X, Scharff MD, MacIntyre J, Zollner RS, Kovalenko OV, Martinez LR, Byrne FR, Fries BC. 2013. Staphylococcal enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections. J Infect Dis 208:2058-2066. http://dx.doi.org/10.1093/infdis/jit421.
8. LeClaire RD, Hunt RE, Bavari S. 2002. Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 70:2278-2281. http://dx.doi.org/10.1128/IAI.70.5.2278-2281.2002.
9. Arad G, Levy R, Hillman D, Kaempfer R. 2000. Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation. Nat Med 6:414-421. http://dx.doi.org/10.1038/74672.
10. Buonpane RA, Churchill HR, Moza B, Sundberg EJ, Peterson ML, Schlievert PM, Kranz DM. 2007. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 13: 725-729. http://dx.doi.org/10.1038/nm1584.
11. Hong-Geller E, Mollhoff M, Shiflett PR, Gupta G. 2004. Design of chimeric receptor mimics with different TcRVbeta isoforms. Typespecific inhibition of superantigen pathogenesis. J Biol Chem 279:5676-5684. http://dx.doi.org/10.1074/jbc.M309388200.
12. Ellington AD, Szostak JW. 1992. Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures. Nature 355:850-852. http://dx.doi.org/10.1038/355850a0.
13. Tuerk C, Gold L. 1990. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249:505-510. http://dx.doi.org/10.1126/science.2200121.
14. Santosh B, Yadava PK. 2014. Nucleic acid aptamers: research tools in disease diagnostics and therapeutics. Biomed Res Int 2014:540451. http://dx.doi.org/10.1155/2014/540451.
15. Bruno JG, Kiel JL. 2002. Use of magnetic beads in selection and detection of biotoxin aptamers by electrochemiluminescence and enzymatic methods. Biotechniques 32:178-180, 182-183.
16. Purschke WG, Radtke F, Kleinjung F, Klussmann S. 2003. A DNA Spiegelmer to staphylococcal enterotoxin B. Nucleic Acids Res 31:3027-3032. http://dx.doi.org/10.1093/nar/gkg413.
17. DeGrasse JA. 2012. A single-stranded DNA aptamer that selectively binds to Staphylococcus aureus enterotoxin B. PLoS One 7:e33410. http://dx.doi.org/10.1371/journal.pone.0033410.
18. Temur E, Zengin A, Boyaci IH, Dudak FC, Torul H, Tamer U. 2012. Attomole sensitivity of staphylococcal enterotoxin B detection using an aptamer-modified surface-enhanced Raman scattering probe. Anal Chem 84:10600-10606. http://dx.doi.org/10.1021/ac301924f.
19. Wang KY, Zeng YL, Yang XY, Li WB, Lan XP. 2011. Utility of aptamerfluorescence in situ hybridization for rapid detection of Pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis 30:273-278. http://dx.doi.org/10.1007/s10096-010-1074-0.
20. Niazi JH, Lee SJ, Kim YS, Gu MB. 2008. ssDNA aptamers that selectively bind oxytetracycline. Bioorg Med Chem 16:1254-1261. http://dx.doi.org/10.1016/j.bmc.2007.10.073.
21. Pauli NT, Kim HK, Falugi F, Huang M, Dulac J, Henry Dunand C, Zheng NY, Kaur K, Andrews SF, Huang Y, DeDent A, Frank KM, Charnot-Katsikas A, Schneewind O, Wilson PC. 2014. Staphylococcus aureus infection induces protein A-mediated immune evasion in humans. J Exp Med 211:2331-2339. http://dx.doi.org/10.1084/jem.20141404.
22. Zuker M. 2003. Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res 31:3406-3415. http://dx.doi.org/10.1093/nar/gkg595.
23. Krakauer T, Buckley M, Issaq HJ, Fox SD. 2010. Rapamycin protects mice from staphylococcal enterotoxin B-induced toxic shock and blocks cytokine release in vitro and in vivo. Antimicrob Agents Chemother 54: 1125-1131. http://dx.doi.org/10.1128/AAC.01015-09.
24. Nagaki M, Muto Y, Ohnishi H, Yasuda S, Sano K, Naito T, Maeda T, Yamada T, Moriwaki H. 1994. Hepatic injury and lethal shock in galactosamine-sensitized mice induced by the superantigen staphylococcal enterotoxin B. Gastroenterology 106:450-458.
25. Pan Q, Zhang XL, Wu HY, He PW, Wang F, Zhang MS, Hu JM, Xia B, Wu J. 2005. Aptamers that preferentially bind type IVB pili and inhibit human monocytic-cell invasion by Salmonella enterica serovar typhi. Antimicrob Agents Chemother 49:4052-4060. http://dx.doi.org/10.1128/AAC.49.10.4052-4060.2005.
26. Challa, S, Tzipori, S, Sheoran A. 2014. Selective evolution of ligands by exponential enrichment to identify RNA aptamers against Shiga toxins. J Nucleic Acids 2014:214929. http://dx.doi.org/10.1155/2014/214929.
27. Vivekananda J, Salgado C, Millenbaugh NJ. 2014. DNA aptamers as a novel approach to neutralize Staphylococcus aureus alpha-toxin. Biochem Biophys Res Commun 444:433-438. http://dx.doi.org/10.1016/j.bbrc.2014.01.076.
28. Kim SK, Sims CL, Wozniak SE, Drude SH, Whitson D, Shaw RW. 2009. Antibiotic resistance in bacteria: novel metalloenzyme inhibitors. Chem Biol Drug Design 74:343-348. http://dx.doi.org/10.1111/j.1747-0285.2009.00879.x.
29. Chen F, Zhang X, Zhou J, Liu S, Liu J. 2012. Aptamer inhibits Mycobacterium tuberculosis (H37Rv) invasion of macrophage. Mol Biol Rep 39:2157-2162. http://dx.doi.org/10.1007/s11033-011-0963-3.
30. Chang YC, Kao WC, Wang WY, Wang WY, Yang RB, Peck K. 2009. Identification and characterization of oligonucleotides that inhibit Tolllike receptor 2-associated immune responses. FASEB J 23:3078-3088. http://dx.doi.org/10.1096/fj.09-129312.
31. Kulbachinskiy AV. 2007. Methods for selection of aptamers to protein targets. Biochemistry (Mosc) 72:1505-1518. http://dx.doi.org/10.1134/S000629790713007X.
32. Kanwar JR, Shankaranarayanan JS, Gurudevan S, Kanwar RK. 2014. Aptamer-based therapeutics of the past, present and future: from the perspective of eye-related diseases. Drug Discov Today 19:1309-1321. http://dx.doi.org/10.1016/j.drudis.2014.02.009.
33. Kong HY, Byun J. 2013. Nucleic Acid aptamers: new methods for selection, stabilization, and application in biomedical science. Biomol Ther 21:423-434. http://dx.doi.org/10.4062/biomolther.2013.085.
34. Diener JL, Daniel Lagasse HA, Duerschmied D, Merhi Y, Tanguay JF, Hutabarat R, Gilbert J, Wagner DD, Schaub R. 2009. Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779. J Thromb Haemost 7:1155-1162. http://dx.doi.org/10.1111/j.1538-7836.2009.03459.x.
35. Floege J, Ostendorf T, Janssen U, Burg M, Radeke HH, Vargeese C, Gill SC, Green LS, Janjic N. 1999. Novel approach to specific growth factor inhibition in vivo: antagonism of platelet-derived growth factor in glomerulonephritis by aptamers.AmJ Pathol 154:169-179. http://dx.doi.org/10.1016/S0002-9440(10)65263-7.